On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now Blog

All posts by Christopher

Social Media Strategies Summit Higher Education: Offering The Latest And Best Practices In Social Media Marketing From Today’s Leading Colleges And Universities

Educators, marketers, social media professionals, thought leaders, and research analysts, are invited to attend the Social Media Strategies Summit Higher Education to be held virtually on October 23-24, 2023, with an optional workshop October 25. The eminent summit aims to reshape the academic landscape with transformative insights, advanced strategies, and unmatched networking opportunities. The summit is committed to revealing the secrets of social media success as it brings together the brightest minds to reveal their unique strategies for growing online communities.

Rewriting the rules of social media promotion and engagement, the Social Media Strategies Summit Higher Education promises to lead the way in higher education transformation. The two-day event will be a game-changer for social media enthusiasts looking to harness the power of digital marketing. With a track record of providing insightful educational experiences, the Social Media Strategies Summit gives people the tools needed to achieve their goals.

Staying at the Forefront of Digital Transformation 

As institutions face the unique challenges of the modern world, the Social Media Strategies Summit Higher Education equips them with the latest insights needed to succeed. The summit will feature panel discussions and interactive sessions where professionals will share proven social media strategies and valuable real-world case studies to drive brand awareness, enrollment, and engagement.

Led by seasoned social media experts, these sessions focus on the art of content planning, data analytics, calendars, creativity, engagement, and more. Attendees will be engrossed with interactive activities, knowledge-sharing, short lectures with small breakout groups, and a chance to ask important questions. It’s a great opportunity for them to connect with solution providers, peers, and professionals in the higher education space. They can explore the latest technologies and share ideas in a learning and collaborative environment. 

Interested participants should enroll for the summit now and be a part of a community that is shaping the future of social media innovation.

Your ticket to the summit also unlocks access to the Corporate Brand Summit on October 26-27.

To learn more, please visit https://ibn.fm/m2yBG.

Amid REE Market Supply Interruptions, Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Presses Forward With Commercial Processing Plant Plans

  • Ucore Rare Metals Inc. is moving forward with a rare earth element (“REE”) processing facility in Louisiana that will help to establish an American base for the REE supply chain
  • The REE supply chain is currently almost exclusively controlled by the People’s Republic of China thanks to China’s responsibility for 36.7 percent of the world’s REE reserves, 63 percent of REE mining capacity and more than 90 percent of REE refining capacity
  • REE price increases this month as a result of temporary production shutdowns in Myanmar and China underscore the market’s sensitivity to supply interruptions resulting from governmental policies
  • Ucore’s RapidSX(TM) solvent extraction process is being developed as an American-based alternative to the industry standard SX process for rare earth refining, and will be used in the Louisiana facility

This month’s shutdown of Myanmar rare earth mining to prepare for inspections sparked short-term stockpiling and upward pricing for metal products such as terbium oxide and dysprosium oxide used in solid-state devices, a reminder of the vulnerability of many tech device rare earth element (“REE”) components to sudden supply chain bottlenecks in Asian nations. It demonstrates how sensitive the REE industry is, and the potential threat posed by nations that dominate related supplies.

“Any extended shutdown of mining in Kachin could be quite damaging for Chinese refineries in Southern China which are reliant upon feedstock from Myanmar,” market analyst David Merriman stated in a Reuters report on the situation, and another analyst, Yang Jiawen, stated that similar environmental inspections in one of China’s major rare earth production hubs also helped fuel the price hikes and worries about supply disruptions (https://ibn.fm/GsPLe).

Because the People’s Republic of China provides a significant amount of REE mining and effectively monopolizes REE processing to extract the metals from mined ore, Western nations have been sounding alarms about their dependence on China’s supply chain and the control the Chinese government can wield over that supply chain.

China is responsible for 36.7 percent of the world’s REE reserves, 63 percent of its mining capacity and more than 90 percent of its refining capacity, according to a January report by Forbes (https://ibn.fm/Rw8Fl). The European Union imports 98 percent of its REE supply from China and the United States gets 78 percent of its supply from the Asian nation.

Canada-based critical technology metals supply chain innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is positioning itself to disrupt Chinese control of REE processing. The company has developed a proprietary REE processing technology it touts as an American improvement on the standard processing technology used throughout the industry and is preparing to commercialize its product by building a network of REE processing facilities, beginning with one in Louisiana it intends to begin work on later this year. 

The Louisiana Strategic Metals Complex [“SMC”] is scheduled to initially process 2,000 metric tons of total rare earth oxides by the end of 2024, increasing to 5,000 metric tons in 2026 (https://ibn.fm/DTTce). Additional SMCs are planned in the United States and Canada as the company grows.

Even with the price increases prompted by the temporary shutdown of processing facilities in Southeast Asia, the market price remains far below the startling peak prices reached just over a decade ago when China restricted exports. Neodymium, a rare earth necessary for products including headphones and hybrid electric cars, shot up from $18.5 per pound to $129 per pound at that time and Samarium, an essential element in missile manufacturing, rose from $8.5 per pound to $66 per pound, for example (https://ibn.fm/OtNBW).

But the skyrocketing prices in 2011 further underscore the importance of a diversified supply chain. Ucore’s preparations for building the Louisiana SMC, including demonstration of how its proprietary RapidSX(TM) solvent extraction process compares to the standard SX process at a Canadian facility, and financing measures that include a $4 million award from the U.S. federal government, are positioning the company to become a leader in domestic REE production in the near future.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

RVL Pharmaceuticals plc (NASDAQ: RVLP) Looking to Capitalize on UPNEEQ’s Significant Potential

  • UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis (ptosis), or low-lying eyelid
  • Clinical studies have shown an average one-millimeter lift of the upper eyelid, with results in as little as five minutes post-dose
  • UPNEEQ(R) is available through RVL Pharmaceuticals’ dedicated e-commerce platform, Elevate, which supports subscription ordering by HCPs and RVL Pharmacy patients
  • RVL is poised to be an integral player in the global medical aesthetic market, which is estimated to reach $18 billion by 2027

RVL Pharmaceuticals (NASDAQ: RVLP), is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis (ptosis, or low-lying eyelids) in adults. The company believes there is significant potential for UPNEEQ(R) to create value for healthcare providers, patients, and shareholders.

“Looking ahead, we believe that UPNEEQ is a significant potential value driver,” noted Brian Markison, RVL’s CEO (https://ibn.fm/A1buv).

UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis, or low-lying eyelid. UPNEEQ(R) was approved in July 2020 and since its debut, medica professionals have been prescribing it for patients. UPNEEQ(R) has garnered significant media attention as well, having been featured in top-tier media outlets including Vogue, Elle, and Allure. Patients can purchase UPNEEQ(R) from eye care and medical aesthetic professionals or through RVL Pharmacy LLC, the company’s wholly owned pharmacy.

This once-daily eye drop has shown an average one-millimeter upper eyelid lift, improving appearance and the superior visual field in patients with a functional deficit. Clinical studies have also shown that patients’ eyelids lift in as little as five minutes post-dose, with the lift effect lasting as long as eight hours. This level of effectiveness presents a viable, more accessible, non-surgical alternative for patients with droopy eyelids, a unique value proposition only available with UPNEEQ(R).

Going forward, the company plans to drive adoption through Elevate, the company’s new e-commerce platform, which allows the company to offer subscription options and serve Business-to-Business-to-Consumer (“B-B-C”) clients.

“We expect that our future marketing mix will shift to the consumer to complement our personal selling efforts across the board,” noted Markison. “Conversions to Elevate, our new e-commerce platform, which is designated to enable us to offer subscription options to all our customers and a B-B-C program for direct purchasing locations, are off to an encouraging start.”

These significant strides will [help to] enable RVL to become a significant player in the medical aesthetics market, which is expected to reach $18 billion by 2027. The company is believed to be positioning itself to take advantage of this market growth, focused on providing an innovative, non-invasive solution to a common problem.

For more information, visit the company’s website at www.RVLPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://ibn.fm/RVLP

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) Commences Diamond Drilling with Third Drill Hole at PCH Project in Brazil

  • The global rare earth elements market is expected to grow from 167.99 million tons in 2023, and to 206.25 million tons by 2028 – growing at a CAGR of 4.19%
  • Since starting the project, Appia has commenced diamond drilling in addition to its current reverse circulation and auger drilling campaigns
  • Specimens from the drilling efforts will be submitted to SGS Geosol laboratory, with assays expected two months from submission

The global rare earth elements (“REE”) market is expected to grow from 167.99 million tons in 2023 to 206.25 million tons by 2028 – growing at a CAGR of 4.19%. The driving factors for the increase in REE production come from a global demand from emerging economies for “green technology” (https://ibn.fm/UuCTZ). With the high growth and demand, several companies are pursuing the REE industry, including Appia Rare Earths & Uranium (CSE: API) (OTCQX: APAAF), a mineral exploration company focused on exploration activities in Brazil and Canada. The company is funded no debt, and has an aggressive exploration program underway.

Appia’s newly acquired Cachoeirinha rare earths project (PCH Project) in Brazil represents important potential for the company. The PCH Project hosts REE mineralization in both ionic clays developed from the weathering of alkaline granites and in-situ rare earth mineralization associated with the area’s underlying granite and a carbonatite intrusion to depths greater than 100 meters. In July 2023, the company commenced an aggressive auger and reverse circulation drill campaign to delineate a potential resource estimate at the PCH Project.

The initial results from the PCH Project drill campaign revealed significant exploration potential and an impressive value that surpasses known ionic clay deposits in Brazil. Terbium and Dysprosium were among the highly valuable heavy rare earths the company uncovered.

In a press release following the July 2023 exploration, Appia CEO Tom Drivas said the company was thrilled with the progress made and the promising results thus far. “The company remains committed to advancing its exploration plans, aiming to promptly gather significant data throughout the year, and to work towards estimating a maiden mineral resource in the coming months,” Drivas added (https://ibn.fm/jYzRX).

Since then, Appia has deployed a third drill hole on-site at the PCH Project to investigate a significant geophysical anomaly at a depth below Target IV. The program was designed to expand on the diamond drilling that was completed in prior seasons. This additional drill hole brings Appia’s exploration of the PCH Project to include three drills – one auger, reverse circulation, and a diamond drill.

“The arrival of the diamond drill marks a pivotal advancement in our exploration initiative,” Appia President Stephen Burega said (https://ibn.fm/CZhSg). “It underscores our commitment to investigating not only the potential genesis of Ionic Adsorption Clay but also the exciting opportunity for REE mineralization in hard rock formations.”

The company’s primary objective is to accurately delineate the extent of mineralization and assess its economic significance. To achieve these efforts, Appia is employing a rigorous sampling procedure – including one-meter samples that will be carefully collected and shipped to SGS Geosol laboratory. Assays from the project are expected within two months from the submission of the specimens.

For more information, visit the company’s website at www.AppiaREU.com.

NOTE TO INVESTORS: The latest news and updates relating to APAAF are available in the company’s newsroom at https://ibn.fm/APAAF

Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study

  • CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer
  • CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’s end
  • The company is also preparing the interim study analysis for release by year’s end, now that more than 50 percent of the planned patient roster has reached a point necessary for effective comparison of performance of the flagship drug, Berubicin, to that of a standard of care chemotherapy agent
  • The company has stated that it took longer than anticipated to launch the interim analysis because many patients were living longer than historical expectations, and CNS hopes to show that Berubicin has helped patients achieve a longer Overall Survival (“OS”), driving eventual commercialization and improved treatments

Cancer drug developer CNS Pharmaceuticals (NASDAQ: CNSP) is closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (“GBM”), with 200 of the expected 243 patients now enrolled in the company’s potentially pivotal study involving its flagship drug candidate Berubicin, according to a company news release (https://ibn.fm/OqKzk).

The Texas-based company has clinical trial sites operating in the U.S., Italy, France, Spain, and Switzerland, to evaluate Berubicin’s performance against standard of care alkylating chemotherapy agent Lomustine for treating recurrent GBM.

GBM has been generally untreatable by anthracyclines because of their inability to cross the blood-brain barrier, but Berubicin is believed to be able to cross the barrier and directly target central nervous system tumors.

CNS Pharmaceuticals’ progress in enrolling patients for its potentially pivotal, global clinical trial indicate the company is on track to not only complete enrollment by the end of the year, but also to issue its planned futility interim analysis by the end of the year.

The interim analysis was triggered when at least 50 percent of the enrolled patients had reached the pre-planned primary efficacy endpoint, allowing an independent Data Safety Monitoring Board (“DSMB”) to review the number of deaths in each arm of the trial to ensure that the overall survival of patients receiving Berubicin shows at least a statistically significant comparison to those receiving Lomustine.

The news release notes that Overall Survival (“OS”) is a rigorous endpoint that the U.S. Food and Drug Administration (“FDA”) has recognized as the basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm, and the DSMB’s review will consider making recommendations on whether to continue the study as planned or to modify it based on patient outcomes thus far.

CNS announced last month that it has taken longer than planned to reach the endpoint for launching the interim analysis because “many patients in this study are living longer than the historical data would suggest they should,” which means it took longer to reach the number of mortality events required to conduct the interim analysis (https://ibn.fm/5G4tw).

“As we have noted previously, patient volunteers and their treating clinicians are the backbone of our Berubicin development program. We are deeply sensitive to the fact that these brave patients are facing the battle of their lives and we are forever in their debt for the trust and confidence they and their treating clinicians have in Berubicin and the company,” CNS CEO John Climaco stated in the most recent company statement on enrollment. “We are pleased to achieve this landmark milestone. Importantly, this takes us one step closer to bringing the study across the finish line and potentially offering an effective treatment in GBM that is safe and well tolerated.”

Berubicin was originally produced by Reata Pharmaceuticals, Inc., in 2006, and a small-scale clinical trial testing Berubicin’s safety at the time produced statistically significant improvements in the two dozen patients, including one who has remained cancer-free during the ensuing years. CNS reached an agreement with Reata in more recent years to advance development of the drug, and launched the global trial in 2021.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

Electronic Servitor Publication Network Inc. (XESP) Helps Businesses Compete and Win Through The Increasingly Recognized Necessity of Marketing Automation

  • XESP, through its Digital Engagement Engine(TM), is making automation, powerful data management, and an advanced workflow, more accessible to B2B companies
  • The company allows businesses to offer buyers meaningful and empowering experiences, making them feel appreciated and understood, and moving them to action
  • XESP understands businesses’ concerns, especially regarding the cost of automation, and continues to refine its products, integrating new features and addressing emerging customer needs, all at a more competitive price point
  • By integrating new features and making new offerings, the company is staying ahead of the competition and stamping its position as a leader in the digital activation and engagement space

Electronic Servitor Publication Network (OTCQB: XESP), a market disruptor for B2B companies, is showing how unique, cutting-edge data analysis and smart technology can grow businesses and help them develop a continuous flow of customers. Through its Digital Engagement Engine(TM), the company is making advanced marketing automation, data management, and an efficient marketing workflow, more accessible to B2B companies, affording them greater reach and lift for their digital content and ensuring greater customer satisfaction and advocacy.

“The Digital Engagement Engine(TM) isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.”

Experts in the industry have noted that automation is no longer an option. With changing customer demands and preferences, big and small businesses are all being forced to embrace new technologies and ways to satisfy these demands. XESP, through its Digital Engagement Engine(TM), offers a unique value proposition for its customers.

For starters, through its offering, XESP allows businesses to generate valued experiences that resonate with buyers. This comes in the form of more efficiently proving a brand’s end value to customers and delivering focused offerings that drive conversion and loyalty. Through its technological offerings, XESP can provide businesses with tools that allow customers to feel appreciated and heard. Superior intelligent automated technologies, when used correctly, are able to identify and respond meaningfully and immediately, addressing the growing need for customers to get a response in 10 minutes or less, a huge determinant of customer satisfaction (https://ibn.fm/M1Bah).

“That meaningful interaction gives a greater relationship with your audience and trust,” noted Peter Hager, XESP’s CEO. “Ultimately, it drives greater growth in your organization and, very simply put, replicates what you do face-to-face,” he added (https://ibn.fm/RRMha).

One of the biggest concerns for businesses is the cost of investing in certain conveniences, technologies, or product offerings. It is a legitimate concern since it counts as an ongoing expense for businesses looking to earn as much profit as possible from selling their products or services. XESP understands this concern, and while its offering is competitively priced, the bottom line is a significant return on investment, one that allows a business to meet their growth and return on investment objectives.

Studies on automation in businesses have validated its importance. For instance, with email and marketing automation, it was noted that for every $1 invested, businesses get $44 back. In addition, triggered emails resulted in eight times more opens and more significant sales than typical batch email sends. This is on top of offering an affordable way to stay connected with customers, an easier way to track and measure metrics, and the benefit of having a more efficient team.

XESP continues to refine its product, integrating new features and addressing emerging customer needs. The company’s understanding of the changing dynamics in the market allows it to stay ahead of the competition, offering products and services that solve real problems and deliver on its promise. This has helped set the company apart from its peers while positioning itself as a leader in its segment.

For more information, visit the company’s website at www.XESPN.com.

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

GolfLync Inc.’s Pebble Beach Sweepstakes Ends October 1, 2023: This is Your Last Chance to Win a Dream Golf Trip to Pebble Beach Resorts

GolfLync, the leading social networking platform for golfers, is thrilled to remind you about the GolfLync Pebble Beach Sweepstakes, your golden opportunity to win the golf trip of a lifetime to the iconic Pebble Beach Resorts, acclaimed as the No. 1 Golf Resort in America.

Pebble Beach Resorts, nestled on California’s breathtaking Monterey Peninsula, offers an unparalleled golfing experience. With its three Top 50 public courses, including the world-famous Pebble Beach Golf Links, golf at Pebble Beach Resorts is an unforgettable journey. From the stunning coastal views at Spanish Bay to the majestic pines of Spyglass Hill, each course presents its own unique challenges and thrills.

As the greatest public golf course in America, as rated by Golf Digest, Pebble Beach has a rich history of hosting prestigious tournaments, including the U.S. Open and, for the first time in 2023, the U.S. Women’s Open. This sweepstakes provides a once-in-a-lifetime opportunity for golf enthusiasts to immerse themselves in the world of championship golf and experience the magic of Pebble Beach firsthand.

The GolfLync Sweepstakes began on April 17 and will conclude on October 1, just before midnight. There’s still time to participate and seize your chance at winning this extraordinary golf trip. To enter, simply download the GolfLync app, available on both Android and iOS platforms, and create an account during the sweepstakes period. By doing so, you will automatically be entered for a chance to win.

The winner of the GolfLync Pebble Beach Sweepstakes will be selected through a random drawing, which will take place on October 4. Following the drawing, the fortunate winner will be notified and provided with all the details to embark on their unforgettable golf adventure at Pebble Beach Resorts.

Don’t miss out on this remarkable opportunity to tee off at one of the world’s most renowned golf destinations. Download the GolfLync app today and take your shot at winning the golf trip of a lifetime.

To review the official rules and eligibility criteria, please visit the GolfLync website: (official rules).

You can download the GolfLync app using the following links:

For more information about GolfLync, visit GolfLync, download the app, and connect with community on FacebookX and LinkedIn

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

ESG Forum (a Sustain SoCal Event) – Moving Toward a Sustainable Future

Investors, policymakers, academicians, technologists, decision-makers, and business owners are invited to attend the ESG Forum (a Sustain SoCal event) to be held at the Cove, UCI Beall Applied Innovation, September 26, 2023. The highly anticipated event offers a unique platform for improving sustainable business practices. Committed to fostering environmental stewardship, the professionals will delve into the key aspects of Environmental, Social, and Governance (“ESG”) practices.

The ESG Forum is an exclusive event focused on fostering actionable insights and meaningful discussions with industry experts. The event provides a favorable platform for participants to learn, collaborate, and connect with business leaders. They will share insights into the key ESG factors that drive balance profitability and business success with positive environmental and social impact.

Implementing Sustainable Business Practices

The one-of-a-kind ESG Forum will provide attendees with a unique opportunity to engage with innovators and thought leaders who have implemented sustainability in their business strategies. The corporate leaders will share their case studies, best practices, and key insights into the integrated ESG principles. They will also share leading-edge technologies and solutions that will support governance structures and improve social impact.

Fostering networking and collaborations, the ESG Forum is committed to contributing towards a positive, sustainable future. The like-minded professionals will leverage this exclusive opportunity to convene and gain up-to-date knowledge about the latest compliance strategies and requirements. The forum will feature keynote addresses and panel discussions to explore unique solutions that help reduce the carbon footprint. By navigating the evolving regulatory landscape, the attendees will be well-equipped to drive innovation through ESG Integration and measure their business performance.

To learn more, please visit https://ibn.fm/ZmRcX

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Building Domestic REE Supply Chain Alternatives for China-dependent Market

  • Ucore Rare Metals Inc. is focused on establishing its proprietary solvent-based solution as a commercially advantageous and important alternative to standard rare earth (“REE”) processing
  • U.S. Trade Representative Katherine Tai recently noted in a media interview that the REE supply chain is dependent on China for production and, to a greater degree, processing once ore has been removed from the ground
  • Ucore’s development of its proprietary RapidSX(TM) REE processing solution promises an environmental impact advantage as well as advantages in cost and Western supply chain control
  • Ucore also controls a rare earth mine prospect in Alaska that anticipates potentially developing someday as a new American REE source

U.S. trade policy makers continue to seek solutions to an economic power imbalance created by the modern tech industry’s dependence on The People’s Republic of China’s for certain metal elements that perform key functions in high-grade batteries.

The batteries supply power to a wide variety of technology used commonly by general consumers and government militaries alike. The near-total supply chain dependence on China for mining and, particularly, processing the ores that contain batteries’ critical rare earth metal elements (“REEs”) has become a significant source of concern among trade negotiators.

“China’s dominant position in the world market now in [rare earths] means that it is able to turn on the faucet and turn off the faucet,” U.S. Trade Representative Katherine Tai said during an August interview with MSNBC (https://ibn.fm/aoAai). “And until we are able to access and create additional supply chains we remain entirely vulnerable to that leverage.”

The imbalance reflects advantages nations such as China may exploit thanks to its nationalized controls over corporate operations, while Western governments maintain a more nuanced involvement in free market operations sustaining private industry.

But critical tech metal supply chain innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is attempting to become a leader in restoring REE supply chain independence to American nations through the development of a competitive REE ore processing solution that improves on the standard SX solvent-based procedures for separating REEs from the mined material they are found in.

Ucore’s proprietary RapidSX(TM) separation process is being developed as a faster, more environmentally conscious REE extraction alternative to the SX process used globally throughout the industry, and the company is preparing to begin construction this year on commercial-scale production facilities in the United States and, later, Canada.

A recent visit by U.S. Embassy staff to a Canadian Ucore facility that directly compares the output of RapidSX(TM) REEs to standard SX REEs “underscores the significance of our work in the rare earth minerals sector and highlights our dedication to pioneering eco-friendly resource solutions,” Ucore VP & COO Mike Schrider (P.E.) stated in a company news release (https://ibn.fm/0tpyt). “We believe that collaborations on an international level will play a pivotal role in shaping the future of sustainable technologies and strengthen our position of applying pioneering technological breakthroughs to bolster our forthcoming commercial rare earth separation facility in Alexandria, Louisiana.”

Tai noted a World Trade Organization case she worked on as a lawyer some years ago in which the WTO successfully objected to China’s decision to “pinch” the market for REEs. While REE prices were high, some domestic REE production resumed, but when prices again fell, American mines again shuttered their operations, she observed.

“China at some point very … smartly recognized the relevance of rare earths, and they started producing and selling to the world market at prices that we could not compete with, and our producers successively shut down,” she said. “(China was) able to pursue coordinated industrial and trade policies that allowed them to corner the market.”

Ucore’s RapidSX process aims to provide an American alternative to REE miners who must currently send their ore overseas to China for processing, and Ucore also anticipates the possibility of developing its own REE source at its Alaskan rare earth mine prospect, which holds more than 4.7 million metric tons of indicated rare earth ore — the equivalent of about 63.5 million pounds of collective rare earth metals, according to a 2015 resource assessment reported by the Alaska Journal of Commerce and shared by Sen. Lisa Murkowski (https://ibn.fm/iR3t9).

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

Charting the Future of Biopharma and Medical Devices: DGE’s 2nd Chief Commercial Officer Summit Convenes Industry Leaders in Philadelphia

DGE invites biotech, pharmaceutical and medical device leaders to attend the 2nd Chief Commercial Officer Summit to be held at The Bellevue Hotel, Philadelphia, PA, October 4-5, 2023. The much-awaited summit aims to chart the remarkable future of the biotech, pharmaceutical and medical device industries. The landmark event will feature a gathering of thought leaders and visionaries dedicated to driving commercial growth in the industry.

The role of Chief Commercial Officers (“CCOs”) has gained more significance with the progression of the life sciences landscape. The 2nd Chief Commercial Officer Summit provides a unique platform to explore key strategies for advancing commercial development, improving product value, and enhancing patient access. The summit explicitly caters to the challenges of the biopharma and medical device sectors, offering customized solutions and insights to the attendees.

Focused on Market Expansion and Patient Access

The 2nd Chief Commercial Officer Summit is committed to fostering brilliance in the biopharma and medical device industries. It’s an incredible platform to build connections, gain insights, and shape the future of commercial excellence. The summit provides attendees with a unique opportunity to explore the options to access new markets and territories, opening new possibilities for expansion and growth. The industry leaders will share their strategies to ensure the profitability and success of the biopharma and medical device products.

Who will attend:

  • Chief Commercial Officers
  • Commercialization Experts
  • Commercial Operations Professionals
  • Product Launch Leaders
  • Market Access Specialists
  • Digital Innovators
  • Reimbursement Specialists
  • Marketing Executives
  • Value Strategists
  • Pricing Experts
  • Gross-to-Net Analysts
  • Franchise Leaders
  • Branding Specialists
  • Sales Leaders
  • Finance Professionals
  • Business Development Executives
  • Licensing Specialists
  • Venture Capitalists
  • Distribution Channel Planners
  • Portfolio Managers

Interested participants should register for the event now.

To learn more, please visit https://ibn.fm/7trPx.

From Our Blog

PaxMedica Inc. (NASDAQ: PXMD) Releases Compelling Video:  Progress Report on ASD and Hope for the Future

September 29, 2023

In a powerful and informative video message, PaxMedica’s (NASDAQ: PXMD) Chairman and CEO, Howard Weisman, shares a progress report on the critical work being done to address the rising prevalence of Autism Spectrum Disorder (“ASD”) in the United States. This disorder has seen a fourfold increase over the past two decades, underscoring the urgency of […]

Rotate your device 90° to view site.